JNJ-AbbVie cancer drug Imbruvica succeeds in late-stage trial

Johnson and Johnson said on Tuesday a combination therapy containing its blockbuster cancer drug Imbruvica significantly improved survival in blood cancer patients, compared with drugs currently used as the standard of care.